Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adrenoceptor alpha 2A |
| Gene Name | ADRA2A |
| Uniprot | P08913 (Human); Q01338 (Mouse) |
| Synonym | ADRA2; ADRAR; ZNF32; ADRA2R; ALPHA2AAR; adrenergic, alpha-2A-, receptor; alpha-2 adrenergic receptor subtype C10; alpha-2-adrenergic receptor, platelet type; alpha-2A adrenoceptor; alpha-2A adrenoreceptor; alpha-2AAR subtype C10 |
| Background | The alpha-2A adrenergic receptor (ADRA2A), a distinct subtype within the broader family of α2 adrenergic receptors, is encoded by the ADRA2A gene in Homo sapiens. This particular genetic locus is notable for its apparent lack of intronic sequences, a characteristic observed in both its coding and untranslated regions. It is important to emphasize that the α2 adrenergic receptors, as a collective group, are typically stratified into three highly homologous subtypes: α2A, α2B, and α2C. Each of these subtypes plays a crucial and often indispensable role in the sophisticated regulation of neurotransmitter release, a process fundamental to the function of both sympathetic nerve terminals and adrenergic neurons residing within the central nervous system. The precise contributions of the ADRA2A subtype, alongside its counterparts, remain an active area of investigation within neurobiology. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX327 | NativeExtract™ Human ADRA2A Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPVLP-003 | MemDX™ Recombinant Human A2AR Membrane Protein in Virus-Like Particles (MP-VLPs) | HEK293 cell | Full length | VLPs |
| MPX3584K | MemDX™ Membrane Protein Human ADRA2A Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| Please for more products or customization | ||||
Z*e: Their responsive technical team resolved optimization queries swiftly.
02/Jun/2023
L**y: Ideal for high-throughput screening.
25/Mar/2024
ADRA2A Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
Targeted Gene Editing
Creative Biolabs offers gene editing services. Gene editing systems offer a transformative avenue for the precise modulation of ADRA2A expression through highly targeted interventions, including both site-specific gene knockouts and knock-ins. This level of control is paramount for dissecting the precise roles of ADRA2A in various physiological and pathological contexts. For instance, compelling evidence from preclinical models has demonstrated that the targeted silencing of ADRA2A can effectively attenuate sympathetic overactivity. This physiological imbalance is a well-established hallmark of essential hypertension, suggesting a potential therapeutic pathway for managing this widespread cardiovascular ailment. This highly precise genetic approach appears particularly promising for addressing a spectrum of disorders inextricably linked to ADRA2A dysregulation, which encompass not only certain cardiovascular diseases but also complex neuropsychiatric conditions.
AAV-Mediated ADRA2A Overexpression
Creative Biolabs offers AAV-mediated ADRA2A overexpression services. Adeno-associated virus (AAV) vectors, specifically engineered to facilitate tissue-specific delivery of ADRA2A transgenes, hold considerable promise for restoring receptor function in various hypoactive states. This targeted genetic intervention offers a sophisticated approach to modulating neuronal activity. For instance, compelling preclinical investigations conducted in rodent models of depression have provided robust evidence. These studies reveal that AAV9-mediated ADRA2A overexpression within the prefrontal cortex can effectively normalize perturbed noradrenergic signaling pathways. This precise modulation subsequently leads to a significant alleviation of anxiety-like behaviors, underscoring the therapeutic potential of such strategies. The availability of proprietary AAV serotype libraries and advanced in vivo delivery optimization services significantly enhances the translational potential of these gene-based therapies for a broad spectrum of neurological applications.
RNA Interference (RNAi) for ADRA2A Suppression
Creative Biolabs offers RNAi services. Small interfering RNAs (siRNAs) designed to target ADRA2A mRNA offer a precise molecular strategy to effectively diminish receptor density within hyperactive signaling pathways. This approach leverages the endogenous RNA interference (RNAi) machinery to reduce the expression of specific genes. Recent advancements in lipid nanoparticle (LNP) encapsulation technologies have significantly expanded the therapeutic potential of these siRNAs. Specifically, LNPs now facilitate the systemic delivery of siRNAs directly to adrenergic neurons, thereby presenting a promising therapeutic avenue for conditions characterized by sympathetic overactivity, such as hypertension and chronic pain. The development of such RNAi-based therapeutics is considerably accelerated by comprehensive, end-to-end platforms that encompass every stage from meticulous siRNA sequence design to rigorous in vivo validation. This integrated approach is critical for expediting the identification of high-potential lead candidates, ultimately facilitating their progression toward clinical translation.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADRA2A cell therapy. Please for more services.
Chimeric Antigen Receptor (CAR) T Cells for Adrenergic Modulation
Creative Biolabs offers CAR T cells development services. Engineered chimeric antigen receptor (CAR)-T cells, specifically those designed to express ADRA2A-specific antibodies, present a novel strategy for selectively modulating adrenergic signaling within tumor microenvironments. ADRA2A-targeted CAR-T cells can effectively reduce catecholamine secretion, a neurochemical process known to influence tumor progression. This reduction in catecholamine levels, in turn, contributes to a notable suppression of tumor growth. Furthermore, specialized services encompassing CAR construct design and ex vivo T-cell expansion are crucial for developing scalable, Good Manufacturing Practice compliant solutions, thereby facilitating the translation of these promising cellular therapies into clinical oncology applications.
Induced Pluripotent Stem Cell (iPSC)-Derived Adrenergic Neurons
Creative Biolabs offers iPSC-derived adrenergic neurons development services. iPSCs, when meticulously differentiated into ADRA2A-expressing neurons, offer a robust and versatile platform for both disease modeling and prospective cell replacement therapies. This innovative approach harnesses the inherent plasticity of iPSCs to generate specific neuronal subtypes relevant to neurological disorders. The direct grafting of these in vitro-derived neurons into affected brain regions has been shown to effectively restore noradrenergic tone, a crucial neurotransmitter balance often perturbed in this neurodegenerative condition. Consequently, this restoration contributes to a significant improvement in observed motor function. To ensure the highest standards for regenerative medicine applications, consistent and reliable cellular products are paramount.
Dendritic Cell Vaccines Targeting ADRA2A
Creative Biolabs offers dendritic cell vaccines targeting ADRA2A development services. Dendritic cells (DCs) that have been strategically pulsed with ADRA2A-derived peptides exhibit a notable capacity to prime adaptive immune responses specifically directed against malignancies that overexpress this particular receptor. This sophisticated immunological approach capitalizes on the antigen-presenting capabilities of DCs to orchestrate a targeted anti-tumor attack. In these studies, the administration of such antigen-loaded DCs robustly induced cytotoxic T-cell activity, which, in turn, led to a significant prolongation of survival. The development of such innovative vaccine strategies for hard-to-treat cancers can be considerably streamlined through specialized services focusing on antigen-loading protocols and comprehensive immunophenotyping.
Leverage Creative Biolabs' end-to-end solutions in gene editing engineering, viral vector development, and cell therapy manufacturing to overcome ADRA2A's complex challenges. to explore custom strategies for your preclinical or clinical-stage programs.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
